scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
40 hedge funds and large institutions have $91.3M invested in scPharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
60% more call options, than puts
Call options by funds: $131K | Put options by funds: $82K
20% more capital invested
Capital invested by funds: $75.9M → $91.3M (+$15.4M)
5% more funds holding
Funds holding: 38 → 40 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.17% less ownership
Funds ownership: 57.34% → 51.18% (-6.2%)
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$270K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$138K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$121K |
| 4 |
RWM
Ritholtz Wealth Management
New York
|
+$80.1K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$75.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$3.15M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.16M |
| 3 |
5VM
5AM Venture Management
San Francisco,
California
|
-$1.21M |
| 4 |
AC
Armistice Capital
New York
|
-$1.11M |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$788K |
SCPH Hedge Fund Activity: Q3 2022 in Review
40 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q3 2022, worth a combined $91.3M — up 20% from $75.9M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SCPH positions and 2 closed out — a net gain of 2 holders — while 9 added to existing stakes and 15 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $270K. The largest seller was AIGH Capital Management, cutting an estimated $3.15M.
- 40 institutional investors held scPharmaceuticals (SCPH) as of Q3 2022, up from 38 in Q2 2022.
- Funds reported $91.3M of scPharmaceuticals stock for Q3 2022, up 20% quarter-over-quarter.
- 4 funds opened new scPharmaceuticals positions in Q3 2022 and 2 closed out, a net change of +2 holders.
- The largest scPharmaceuticals buyer in Q3 2022 was J. Goldman & Co, an estimated $270K added.
- The largest scPharmaceuticals seller in Q3 2022 was AIGH Capital Management, an estimated $3.15M sold.
Based on aggregated 13F filings for Q3 2022.